Pages that link to "Q64449891"
Jump to navigation
Jump to search
The following pages link to A search for serologic correlates of immunity to Bordetella pertussis cough illnesses (Q64449891):
Displaying 50 items.
- Pertussis: challenges today and for the future (Q21131377) (← links)
- Acellular vaccines for preventing whooping cough in children (Q24193554) (← links)
- Acellular vaccines for preventing whooping cough in children (Q24201103) (← links)
- Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies (Q24522458) (← links)
- FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection (Q28504795) (← links)
- Specific antibodies against vaccine-preventable infections: a mother-infant cohort study (Q28706294) (← links)
- Immunology of gut mucosal vaccines (Q28972559) (← links)
- Neutralizing antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils (Q30453704) (← links)
- Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations (Q30485533) (← links)
- Serum reactome induced by Bordetella pertussis infection and Pertussis vaccines: qualitative differences in serum antibody recognition patterns revealed by peptide microarray analysis (Q30656264) (← links)
- Characterization of a key neutralizing epitope on pertussis toxin recognized by monoclonal antibody 1B7. (Q30877920) (← links)
- Impact of age and vaccination history on long-term serological responses after symptomatic B. pertussis infection, a high dimensional data analysis (Q31154853) (← links)
- Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data (Q31159257) (← links)
- Construction and characterization of single-chain variable fragment antibodies directed against the Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin (Q33295282) (← links)
- Association of interacting genes in the toll-like receptor signaling pathway and the antibody response to pertussis vaccination (Q33382988) (← links)
- Estimating the duration of pertussis immunity using epidemiological signatures (Q33513972) (← links)
- Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis (Q33521111) (← links)
- Type V protein secretion pathway: the autotransporter story (Q33559645) (← links)
- Bordetella pertussis proteins dominating the major histocompatibility complex class II-presented epitope repertoire in human monocyte-derived dendritic cells (Q33601872) (← links)
- Suppression subtractive hybridization identifies an autotransporter adhesin gene of E. coli IMT5155 specifically associated with avian pathogenic Escherichia coli (APEC) (Q33688493) (← links)
- Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection (Q33738499) (← links)
- Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis va (Q33768673) (← links)
- Immunoproteomic Analysis of Human Serological Antibody Responses to Vaccination with Whole-Cell Pertussis Vaccine (WCV) (Q33775443) (← links)
- Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis. (Q33825642) (← links)
- Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs (Q33856133) (← links)
- Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads (Q33916408) (← links)
- Pertactin is required for Bordetella species to resist neutrophil-mediated clearance. (Q33963245) (← links)
- Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland (Q34001270) (← links)
- Immunoglobulin A-mediated protection against Bordetella pertussis infection (Q34008531) (← links)
- Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom (Q34008925) (← links)
- Antibody responses to Bordetella bronchiseptica in vaccinated and infected dogs. (Q34065708) (← links)
- Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis (Q34126969) (← links)
- Pertussis-specific memory B-cell and humoral IgG responses in adolescents after a fifth consecutive dose of acellular pertussis vaccine (Q34260834) (← links)
- A novel group of Moraxella catarrhalis UspA proteins mediates cellular adhesion via CEACAMs and vitronectin (Q34438142) (← links)
- Acellular pertussis vaccine safety and efficacy in children, adolescents and adults (Q34558806) (← links)
- Maternal immunity provides protection against pertussis in newborn piglets (Q34601948) (← links)
- An Autotransporter Protein from Orientia tsutsugamushi Mediates Adherence to Nonphagocytic Host Cells (Q34740162) (← links)
- Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. (Q34759839) (← links)
- Loss of multi-epitope specificity in memory CD4(+) T cell responses to B. pertussis with age. (Q35082532) (← links)
- Lack of association between mannose binding lectin and antibody responses after acellular pertussis vaccinations (Q35099727) (← links)
- Development and clinical testing of multivalent vaccines based on a diphtheria–tetanus–acellular pertussis vaccine: difficulties encountered and lessons learned (Q35126727) (← links)
- T-cell immune response assessment as a complement to serology and intranasal protection assays in determining the protective immunity induced by acellular pertussis vaccines in mice. (Q35140321) (← links)
- Characterization of the key antigenic components of pertussis vaccine based on outer membrane vesicles (Q35266726) (← links)
- Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG anti-PT enzyme-linked immunosorbent assays (Q35666201) (← links)
- Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains (Q35690068) (← links)
- Age-related differences in patterns of increased Bordetella pertussis antibodies (Q35867249) (← links)
- Nonhuman primate model of pertussis (Q35867565) (← links)
- Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice (Q35946895) (← links)
- What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine (Q36226482) (← links)
- Antibody-mediated neutralization of pertussis toxin-induced mitogenicity of human peripheral blood mononuclear cells (Q36228236) (← links)